Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCADIA Study of ramipril versus non-RAS inhibitor therapy in chronic dialysis patients
2008-003529-17Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ramipril in hypertension (HTN), left ventricular hypertrophy (LVH) and end-stage kidney disease (ESKD) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Composite cardiovascular outcome. Started Oct 2008; status: completed.
02
Drugs
ramipril
03
Conditions
hypertension (HTN)left ventricular hypertrophy (LVH)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2008-003529-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003529-17.